ANA Has Treated Over 100 Patients with New Alzheimer’s Disease Medication
This treatment, and these 100 people, represent a new era in Alzheimer’s treatments.
ANA Has Treated Over 100 Patients with New Alzheimer’s Disease Medication Read More »
Denied Alzheimer’s Coverage: The Uphill Battle Against Insurance Companies
Some insurance companies may be discriminating against early stage Alzheimer’s patients.
Denied Alzheimer’s Coverage: The Uphill Battle Against Insurance Companies Read More »
Dr. Weisman and His Patients Featured in Article About MCI
In neurology we learn the same lessons again and again: Time is brain.
Dr. Weisman and His Patients Featured in Article About MCI Read More »
ANA Featured in Washington Post Article About Leqembi
Lecanemab has not been as widely tested in Black patients.
ANA Featured in Washington Post Article About Leqembi Read More »
Dr. Weisman Quoted in Article about Quest Rapid Alzheimer’s Test
Almost anyone can take this quick test for Alzheimer’s without even going to the doctor. It’s a terrible idea.
Dr. Weisman Quoted in Article about Quest Rapid Alzheimer’s Test Read More »
An Open Letter to Highmark and Independence Blue Cross
Denial of coverage for lecanemab will have devastating consequences for millions of patients and families.
An Open Letter to Highmark and Independence Blue Cross Read More »
FDA Converts Lecanemab to Traditional Approval
Leqembi is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer’s disease.
FDA Converts Lecanemab to Traditional Approval Read More »
Dr. Klein Receives American Headache Society Distinguished Service Award
This recognition is a testament to Dr. Klein’s expertise and the high-quality headache care we deliver at Abington Neurological Associates.
Dr. Klein Receives American Headache Society Distinguished Service Award Read More »
Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen
On March 22, Weisman and his fellow advisers voted unanimously that the drug was ‘reasonably likely’ to prove beneficial, paving the way for the agency to approve it Tuesday.
Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen Read More »
FDA Gives Accelerated Approval to New ALS Treatment
Tofersen, an injection treatment for a rare form of ALS, has been approved under the accelerated approval pathway.
FDA Gives Accelerated Approval to New ALS Treatment Read More »
